Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. - Wikidata - awgldk - TriplyDB

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

http://www.wikidata.org/entity/Q33498422

about

Problems monitoring response in multiple myeloma Fifty years of melphalan use in hematopoietic stem cell transplantation Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers Salvage second hematopoietic cell transplantation in myeloma Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial The role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursing NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.Curing myeloma at last: defining criteria and providing the evidence.Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3 Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system.Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.Suppression of abnormal karyotype predicts superior survival in multiple myeloma.First thalidomide clinical trial in multiple myeloma: a decade.Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.Stem cell transplantation for multiple myeloma: current and future status Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation.The Arkansas approach to therapy of patients with multiple myeloma.Cure models as a useful statistical tool for analyzing survival.Retrospective analysis of peripheral blood stem cell transplantation for the treatment of high-risk neuroblastoma Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).Treatment of myeloma: cure vs control IRF4: Immunity. Malignancy! Therapy?Double autologous stem cell transplantation for multiple myeloma: a Korean single center study.Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor Therapy-related myeloid malignancies in myeloma Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

P2860

Q24676888-C037251E-CE4C-462B-82F8-10C6A5F711A9 Q26824498-E8E4DF6B-6AF9-4D28-9A54-20BF765560D0 Q26851202-227906CA-CF84-4842-AE0D-7734243DBB0B Q30416452-8EBC44AF-06E7-4938-906F-47067B3DE53B Q33687086-1B926447-6949-49AB-9842-4B930F2B402B Q33710994-22AF2A7F-144E-4661-B7FB-39FA142C3312 Q33788682-66AF4FA5-1340-44E9-8AD2-43832632C49C Q33956059-0C1620A9-C7A6-49DE-B967-A96792AE30FB Q34361282-76A58C85-0E61-4969-94BB-C62DC18A6F36 Q34388367-332EE64D-55E8-4CC8-B3F1-10E3C2FC4105 Q34485950-F75E9325-E298-4D91-8FC3-D77D42A682C6 Q34508313-560772CE-3AA5-47D5-95C2-90F1782FEA60 Q34557946-EBC1F61B-B2E3-4292-BF3A-E9EBC198A1F7 Q35097338-170A0F66-B649-4D6A-9B2D-55F94E8A67D6 Q35157385-33EF2AFC-CD77-441D-9DEB-C6E6E5F8201E Q35166712-0F6513E0-D54E-422D-8EA4-5618F97861E8 Q35569350-FD2F1282-B6F8-42E1-B6AE-1DA9C5FD4E14 Q35651705-89F1C6C8-30C0-4C0B-A181-2004AC2863B4 Q35849614-5C30B40B-D691-4BCC-8354-0B3C3DE288B5 Q36018407-5E9558E3-00FC-4707-9EA7-8A3F5FADDEDC Q36083211-03CDCDE5-3AB6-4530-8A27-8A5FB3E9485F Q36384679-7D975728-70A5-452F-9853-44405FCB6B12 Q36570256-800FF6DF-FADC-44F9-84F4-E68A87C75F72 Q36806543-13C2FB28-4F1F-4C57-B6C0-720E1A117C64 Q36831384-3AA409AD-2A29-4DC8-B53D-AF6B4F9F96E2 Q36831389-8FBD01FC-79EB-4A56-BE2A-2EDC5467073A Q36835212-22597B96-25BC-4DBD-A551-22254C0EDDB6 Q36848183-A10BB2A1-FECB-4C5F-82FD-E27915361FCE Q36852229-9BD3C503-7AE8-45FC-AA92-3110CA48BC38 Q36951074-65E0F481-3464-4E89-8488-99793A1492CE Q37028586-A360902E-FBDF-4F9C-BA5F-CF0929D5E3A3 Q37096671-A0877D9D-BE64-481E-9264-35054166EBC3 Q37222520-C95A5B11-F6D8-4E54-B1F9-C7FED96E1FF9 Q37280737-BF17D4A1-0EF0-4C15-96F5-E6F3F993C681 Q37284081-7AD0AAD4-A9EB-4286-94FB-74003F1F5680 Q37454043-9B995CCB-98EE-4B4C-A283-3F9E106A913B Q37476203-8EDBB47D-3D47-4BC7-8297-64A358A85679 Q37718563-AC57BA74-26CB-49E8-B635-A8E13A0A4682 Q39209765-205CEAC2-B1A9-47CC-A233-7416E08E1C91 Q41760786-846BC4A2-2448-4182-9775-1FF756EA37EC

P2860

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

http://www.wikidata.org/entity/Q33498422

description

1997 nî lūn-bûn

@nan

1997 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Superiority of tandem autologo ...... ly untreated multiple myeloma.

@ast

Superiority of tandem autologo ...... ly untreated multiple myeloma.

@en

type

label

Superiority of tandem autologo ...... ly untreated multiple myeloma.

@ast

Superiority of tandem autologo ...... ly untreated multiple myeloma.

@en

prefLabel

Superiority of tandem autologo ...... ly untreated multiple myeloma.

@ast

Superiority of tandem autologo ...... ly untreated multiple myeloma.

@en

P1433

Q33498422-A3F18639-9DA7-454C-AB73-617C01638D82

P1476

Q33498422-CA10DCAE-9B42-4DBB-A43D-2D31599A42F7

P2093

Q33498422-04FC4922-1EE8-433F-93C3-126FA95D584C

Q33498422-5644BA30-5EA5-4664-847D-8810E446998F

Q33498422-56F2E72E-ED86-4DDC-B214-9E92A4976E80

Q33498422-9251E4D3-B5BD-4335-A01F-DF5AC3027C4A

Q33498422-99F8FD1B-24FF-4090-958A-923864D9A935

Q33498422-AB085DEB-CFB7-44F6-BE54-88E4AEAB3B1D

Q33498422-C74ECE55-F8E0-4F71-8898-0D355F6537AE

Q33498422-C7F15235-F9DD-4226-8CD8-34128C7F5D1B

Q33498422-D6B40A7B-A98F-4E48-95A5-D926563BEDE1

Q33498422-F50C11D4-9A10-4D50-8451-21B9B1ABE978

P304

Q33498422-EEBA0EE7-F45D-4B4D-8A1E-8B7C0D2F31A9

P31

Q33498422-9532108A-5D4E-4237-A62A-9BCD4E1508EC

P407

Q33498422-0E575C3D-C313-4F7C-B5E7-C4270DC43B30

P433

Q33498422-37A8872B-1F73-4E6A-956B-7140DF694226

P478

Q33498422-9AF43CE9-104C-4D3A-B2F6-09870DED5213

P577

Q33498422-502758E7-9589-4AF4-8287-24AD760FF672

P698

Q33498422-DFAB4D2B-AE4F-4AC9-BBC9-42FC3703416C

P1433

P1476

Superiority of tandem autologo ...... sly untreated multiple myeloma

@en

P2093

Barlogie B

http://www.w3.org/2001/XMLSchema#string

Bracy D

http://www.w3.org/2001/XMLSchema#string

Cheson B

http://www.w3.org/2001/XMLSchema#string

Crowley J

http://www.w3.org/2001/XMLSchema#string

Jacobson J

http://www.w3.org/2001/XMLSchema#string

Jagannath S

http://www.w3.org/2001/XMLSchema#string

Mattox S

http://www.w3.org/2001/XMLSchema#string

Naucke S

http://www.w3.org/2001/XMLSchema#string

Salmon S

http://www.w3.org/2001/XMLSchema#string

Tricot G

http://www.w3.org/2001/XMLSchema#string

P304

789-793

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

1997-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9028309

http://www.w3.org/2001/XMLSchema#string